Literature DB >> 28385052

Perinatal SSRI exposure permanently alters cerebral serotonin receptor mRNA in mice but does not impact adult behaviors.

Lauritz R Meyer1, Benjamin Dexter2, Cecilia Lo2, Elizabeth Kenkel2, Takahito Hirai3, Robert D Roghair4, Sarah E Haskell4.   

Abstract

PURPOSE: Associations have been made between maternal selective serotonin reuptake inhibitor (SSRI) use during pregnancy and altered behavior in offspring, including an increased risk of autism. Given the important role serotonin plays in behavior, we hypothesized SSRI exposure in the perinatal period would alter central serotonin receptor expression and program adult behaviors in mice.
METHODS: Female mice were injected with sertraline or saline throughout pregnancy. Offspring continued to receive injections on postnatal days 1-14, a time period in mice similar to the third trimester in human pregnancy. Adult offspring underwent behavioral testing, and serotonin receptor mRNA levels were quantified.
RESULTS: Compared to controls, SSRI exposed mice did not have a reduction in social interactions, spatial learning, or exploratory behavior. As adults, sertraline exposed mice had significantly increased mRNA levels of multiple 5-HT receptors, serotonin transporter (5-HTT), and tryptophan hydroxylase isoform 2 in the cerebral cortex.
CONCLUSION: Although no behavioral phenotype was observed, SSRI exposure in the perinatal period permanently alters cerebral receptor mRNA levels. We speculate these shifts in mRNA expression provide important compensation during SSRI exposure. Further pre-clinical and clinical investigation into additional serotonin-regulated phenotypes is necessary to further assess the long-term implications of perinatal SSRI exposure.

Entities:  

Keywords:  Maternal depression; behavior; development; mice; selective serotonin reuptake inhibitors

Mesh:

Substances:

Year:  2017        PMID: 28385052      PMCID: PMC6114087          DOI: 10.1080/14767058.2017.1317342

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  40 in total

1.  Recent trends in selective serotonin reuptake inhibitor use in pregnancy.

Authors:  Christina L Wichman; Amy Fothergill; Katherine M Moore; Tara R Lang; Robert H Heise; William J Watson
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

Review 2.  Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions.

Authors:  Kelan L H Thomas; Vicki L Ellingrod
Journal:  Pharmacotherapy       Date:  2009-07       Impact factor: 4.705

3.  Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response.

Authors:  Tim F Oberlander; Ruth Eckstein Grunau; Colleen Fitzgerald; Ann-Louise Ellwood; Shaila Misri; Dan Rurak; Kenneth Wayne Riggs
Journal:  Pediatr Res       Date:  2002-04       Impact factor: 3.756

4.  Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation.

Authors:  Tuija Heikkinen; Ulla Ekblad; Pertti Palo; Kari Laine
Journal:  Clin Pharmacol Ther       Date:  2003-04       Impact factor: 6.875

Review 5.  Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species.

Authors:  Bridgette D Semple; Klas Blomgren; Kayleen Gimlin; Donna M Ferriero; Linda J Noble-Haeusslein
Journal:  Prog Neurobiol       Date:  2013-04-11       Impact factor: 11.685

6.  In utero exposure to selective serotonin reuptake inhibitors and risk for autism spectrum disorder.

Authors:  Nicole B Gidaya; Brian K Lee; Igor Burstyn; Michael Yudell; Erik L Mortensen; Craig J Newschaffer
Journal:  J Autism Dev Disord       Date:  2014-10

7.  Up-regulation of tryptophan hydroxylase-2 mRNA in the rat brain by chronic fluoxetine treatment correlates with its antidepressant effect.

Authors:  G T Shishkina; T S Kalinina; N N Dygalo
Journal:  Neuroscience       Date:  2007-09-14       Impact factor: 3.590

8.  Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.

Authors:  Marian K Bakker; Pieternel Kölling; Paul B van den Berg; Hermien E K de Walle; Lolkje T W de Jong van den Berg
Journal:  Br J Clin Pharmacol       Date:  2007-10-22       Impact factor: 4.335

9.  Prenatal SSRI use and offspring with autism spectrum disorder or developmental delay.

Authors:  Rebecca A Harrington; Li-Ching Lee; Rosa M Crum; Andrew W Zimmerman; Irva Hertz-Picciotto
Journal:  Pediatrics       Date:  2014-04-14       Impact factor: 7.124

10.  Serotonin modulation of cortical neurons and networks.

Authors:  Pau Celada; M Victoria Puig; Francesc Artigas
Journal:  Front Integr Neurosci       Date:  2013-04-19
View more
  5 in total

Review 1.  Early-life exposure to selective serotonin reuptake inhibitors: Long-term effects on pain and affective comorbidities.

Authors:  Mathilde Baudat; Anne R de Kort; Daniel L A van den Hove; Elbert A Joosten
Journal:  Eur J Neurosci       Date:  2021-12-16       Impact factor: 3.698

2.  Perinatal exposure to fluoxetine and maternal adversity affect myelin-related gene expression and epigenetic regulation in the corticolimbic circuit of juvenile rats.

Authors:  Anouschka S Ramsteijn; Rikst Nynke Verkaik-Schakel; Danielle J Houwing; Torsten Plösch; Jocelien D A Olivier
Journal:  Neuropsychopharmacology       Date:  2022-01-31       Impact factor: 8.294

3.  Brain hyperserotonemia causes autism-relevant social deficits in mice.

Authors:  Miho Tanaka; Atsushi Sato; Shinya Kasai; Yoko Hagino; Hiroko Kotajima-Murakami; Hirofumi Kashii; Yukio Takamatsu; Yasumasa Nishito; Masumi Inagaki; Masashi Mizuguchi; F Scott Hall; George R Uhl; Dennis Murphy; Ichiro Sora; Kazutaka Ikeda
Journal:  Mol Autism       Date:  2018-11-26       Impact factor: 7.509

Review 4.  Gestational Factors throughout Fetal Neurodevelopment: The Serotonin Link.

Authors:  Sabrina I Hanswijk; Marcia Spoelder; Ling Shan; Michel M M Verheij; Otto G Muilwijk; Weizhuo Li; Chunqing Liu; Sharon M Kolk; Judith R Homberg
Journal:  Int J Mol Sci       Date:  2020-08-14       Impact factor: 5.923

5.  Pre-reproductive stress and fluoxetine treatment in rats affect offspring A-to-I RNA editing, gene expression and social behavior.

Authors:  Hiba Zaidan; Gokul Ramaswami; Michal Barak; Jin B Li; Inna Gaisler-Salomon
Journal:  Environ Epigenet       Date:  2018-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.